Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review

Rheumatology

Volumn 50, Issue 12, 2011, Pages 2297-2305

  Hadjinicolaou, Andreas V ^a   Nisar, Muhammad K ^a   Bhagat, Shweta ^a   Parfrey, Helen ^b   Chilvers, Edwin R ^b   Östör, Andrew J K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anti TNF; Biologics; Lung disease; Rheumatoid arthritis; Treatment

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; CERTOLIZUMAB; GOLIMUMAB; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

ALLERGIC PNEUMONITIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG MANUFACTURE; FIBROSING ALVEOLITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; BIOLOGICAL AGENTS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; LUNG DISEASES; POLYETHYLENE GLYCOLS; RHEUMATIC DISEASES;

EID: 82355170761     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker289     Document Type: Article

References (74)

1. Blumenauer B, Judd M, Wells G et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;3:CD003785.
2. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999;21:75-87;discussion 71-2.
3. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
4. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005;3:CD005113.
5. Furst DE. Certolizumab pegol-what role does this new TNF inhibitor have in the treatment of RA? Nat Clin Pract Rheumatol 2009;5:134-5.
6. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-6.
7. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010; 1:CD008341.
8. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008;65:1413-8.
9. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010;3:81-9.
10. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118-25.
11. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;1:CD005121.
12. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010;37: 234-45.
13. Ostor AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 2008;27:1343-53.
14. Bagust A, Boland A, Hockenhull J et al. Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2009;13(Suppl. 2):23-9.
15. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
16. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006;20:915-28.
17. Korhonen R, Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2010;106:13-21.
18. Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848.
19. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 2005;72:46-7.
20. Wolfe F, Rasker JJ, Boers M et al. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007;57:935-42.
21. Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
22. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
23. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-55.
24. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345: 1098-104.
25. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
26. van Ingen J, Boeree MJ, Dekhuijzen PN et al. Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumatol 2008;4:649-56.
27. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
28. Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010;40:147-63.
29. Thavarajah K, Wu P, Rhew EJ et al. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med 2009;103:661-9.
30. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis. Rheum 2011. Advance Access published 28 January 2011, doi:10.1016/j.semarthrit.2010.11.002.
31. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
32. Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum 2009; 60(Suppl. 10):1149.
33. Kishi J, Nanki T, Watanabe K et al. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology 2009;48: 447-8.
34. Leon RJ, Gonsalvo A, Salas R et al. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004;79:949-53.
35. Soubrier M, Jeannin G, Kemeny JL et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008;75:362-5.
36. Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17:191-7.
37. Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9.
38. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
39. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
40. Kawashiri SY, Kawakami A, Sakamoto N et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2010; May 18 [Epub ahead of print].
41. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010;25:1-17.
42. Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
43. Inman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
44. Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68: 789-96.
45. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374: 210-21.
46. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
47. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
48. Weinblatt M, Combe B, Covucci A et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16.
49. Falagas ME, Manta KG, Betsi GI et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007;26: 663-70.
50. Lee HK, Kim DS, Yoo B et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005;127:2019-27.
51. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006;12: 346-53.
52. Olson AL, Swigris JJ, Sprunger DB et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372-8.
53. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004;33:65-72.
54. Bilgici A, Ulusoy H, Kuru O et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005;25: 429-35.
55. Gochuico BR, Avila NA, Chow CK et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168:159-66.
56. Gizinski AM, Mascolo M, Loucks JL et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009;28:611-3.
57. Ananthakrishnan AN, Attila T, Otterson MF et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:682-8.
58. Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997;23:917-37.
59. Parry SD, Barbatzas C, Peel ET et al. Sulphasalazine and lung toxicity. Eur Respir J 2002;19:756-64.
60. Ostor AJ, Chilvers ER, Somerville MF et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33:622-8.
61. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006;33:1189-93.
62. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004;33: 276-7.
63. Dixon WG, Watson KD, Lunt M et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086-91.
64. Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 2005;128:526S-32S.
65. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:357-63.
66. Mattyasovszky SG, Hofmann A, Brochhausen C et al. The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts. Arthritis Res Ther 2010;12:R4.
67. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000;86: 1259-65.
68. Sullivan DE, Ferris M, Pociask D et al. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005;32:342-9.
69. Piguet PF, Ribaux C, Karpuz V et al. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993;143: 651-5.
70. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-8.
71. Belperio JA, DiGiovine B, Keane MP et al. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 2002;73:591-9.
72. Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63: 1062-8.
73. Fleischmann RM, Tesser J, Schiff MH et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12.
74. Harada N, Sayama K, Tanaka K et al. [Long-term treatment with a humanized anti-interleukin-6 receptor antibody (tocilizumab), improving interstitial pneumonia in a patient with multicentric Castleman disease]. Nihon Kokyuki Gakkai Zasshi 2010;48: 145-50.